/ case study

participation of KZ media in regional press conference

ClientBoehringer Ingelheim
ExpertisePR Services
Client Boehringer Ingelheim Expertise PR Services Industry Healthcare


To mark empagliflozin’s approval in the EU for the treatment of adults with chronic kidney disease, Boehringer Ingelheim has held a press conference in its Regional Vienna Center with the goal to secure participation of media from the whole region, including Kazakhstan. 


In order to have Kazakhstani tier1 medical media present at the event, Action team has undertaken the following activities: ​

  • Selection and invitation of 2 tier1 media for online participation​
  • Arrangement of simultaneous translation during the event​
  • Translation of press kit, including press text, infographics, speakers bios​
  • Translation to RU and KZ languages of press conference summary​
  • Provision of necessary additional information upon journalists requests​
  • Fact-checking and confirming articles generated after the press conference with BI KZ team​
  • Result: dedicated articles on pharmnewskz.com and pharm.reviews


  • 2 tier1 medical journalists​
  • 4 press materials localized​
  • >500​ reads of two generated articles​

let’s work together